Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06498349

Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl

The focus of the study is on patients Parkinson's disease showing as well behavioral disorders that can be described as pathological and are summarized under the term impulse control disorder (ICD). Changes in behavior and also pathological disorders are a common side effect of treatment for Parkinson's disease. The goal of this academic study is to compare the effect of surgical (deep brain stimulation, DBS) treatment combined with a coordinated and adapted best medical treatment (BMT) to be compared with the effect of optimized best medical treatment (BMT) alone. The stimulation arm (DBS+BMT) as well as the medication arm (BMT only) will be monitored according to clinical routine. Participants will have to agree to be randomly assigned to either deep brain stimulation in combination with the best medical treatment (DBS group) or the best medical treatment alone (BMT group). Participants will have to come regularly according to clinical routine to the clinic and complete various questionaires and scales for the study.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Cologne, Cologne, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age at the time of enrollment: ≤ 70 years
  • Diagnosis of PD according to MDS clinical diagnostic criteria
  • Onset of first PD motor symptoms ≥ 4 years
  • Moderate or severe impulse control disorder or related behavioral disorders according to Ardouin, with at least 1 score greater than or equal to 3 (or at least 2 scores greater than or equal to 2) on the Ardouin behaviour scale with the following items considered to reflect ICBDs or related behaviors: pathological gambling, hypersexuality, shopping, eating, hobbyism, punding and compulsive medication use
  • MDS-UPDRS III improvement of ≥ 30% in the standardized levodopa test or classical Parkinsonian tremor at rest
  • Adaptation of medical therapy has been attempted
  • MoCA ≥ 24 in the meds on condition
  • BDI-II score < 20 in the meds on condition, or Patients with moderately severe depression with a BDI-II between 20 and 28 points, strict consideration must be made with the involvement of a psychiatrist. Patients must be willing and able to comply this.
  • Patients able to understand the study requirements and the treatment procedures
  • Written informed consent before any study-specific tests or procedures are performed

Exclusion criteria

  • Surgical contraindications to undergo DBS operation
  • Ongoing severe depression (BDI-II > 28)
  • suicidal ideation (item 9 of BDI-II > 1)
  • Dementia (MoCA < 24) in the meds on condition
  • Any prior movement disorder treatments that involved intracranial surgery/ablation or intracranial device implantation
  • Any other active implanted device that is likely to interfere with the implantation or functioning of the DBS system
  • Simultaneous participation in another clinical trial targeting or potentially interfering with ICD
  • Any history of recurrent seizures or haemorrhagic stroke
  • Fertile women not using adequate contraceptive methods
  • Any terminal illness with significantly reduced life expectancy which exclude DBS implantation according to standard clinical care
  • A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception
  • Any impairment that would limit subject's ability to participate in the study and perform study procedures
  • Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints

Treatment and study plan

bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment

Procedure

according to widely accepted expert consensus paper

Other names: best medical treatment for management of impulse control in Parkinson´s disease

best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations

Drug

according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.

Primary outcomes

  1. Ardouin Scale of Behaviour in Parkinson's Disease (ASBPD)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups with respect to the hyperdopaminergic sub-score

Secondary outcomes

  1. Questionnaire for Impulsive-Compulsive Disorders in Parkinson Disease Rating Scale (QUIP RS)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  2. Starkstein-Apathy-Scale (SAS)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  3. Hospital Anxiety and Depression Scale (HADS)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  4. Beck Depression Inventory (BDI)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  5. suicidal item 9 of the BDI

    Time frame: 12 months

    safety focus on suicidal item 9 of the BDI with reference to the question for the last 2 months

  6. Neuropsychiatric-fluctuations scale (NFS)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  7. Young mania rating scale (YMRS)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  8. Quality of life (PDQ-39) measured by Parkinson Disease Questionaire-39 Summary Index

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  9. Zarit Burden Interview ( ZIB) for the change of burden assessment in caregivers using the brief version

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  10. MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (parts I-IV med on/med off and stim on/stim off; if applicable

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  11. Marconi Dyskinesia Rating Scale

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  12. Levodopa-equivalent/dopamine-agonist dosage (LEDD) and other medication

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  13. Pittsburgh Sleep Quality Index (PSQI)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  14. Safety weight monitoring (BMI control)

    Time frame: 12 months

    Difference of change from baseline to follow-up between the two treatment groups

  15. Montreal Cognitive Assessment (MoCA)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  16. Clinical Global Impression (CGI-S, Severity) (CGI-C, Change)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  17. Patient Global Impression (PGI-S, Severity) (PGI-C, Change)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  18. Parkinson's disease Dysarthria Compound Score (PD-DCS) (Speech assessment)

    Time frame: 12 months

    Difference of change (improvement) from baseline to follow-up between the two treatment groups

  19. Adverse events

    Time frame: 12 months

    Reporting and analysis of adverse events: Frequency, type and severity of therapy related relevant adverse events of medication or DBS

  20. Parkinson's disease Dysarthria Compound Score (PD-DCS)

    Time frame: 12 months

    An intra-group comparison will be performed between the individual patient's safety speech outcome of Parkinson's disease Dysarthria Compound Score (PD-DCS) The PD-DCS is a speech acoustic summary measure of the main speech affected domains in PD, namely monopitch, monoloudness, imprecise consonants, inappropriate silences, harsh/breathy voice, and speech timing abnormalities. Acoustic proxy measures of these perceptual speech domains can be extracted from speech using modern acoustic speech analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Guenther Deuschl, Prof.

CONTACT

[email protected]

Steffen Paschen, MD

CONTACT

[email protected]

+49 (0)431 500 ext. 23819

Sponsors and collaborators

Lead sponsor

University of Kiel

Other

Collaborators

  • Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
  • Czech Technical University in Prague
  • Insel Gruppe AG, University Hospital Bern
  • Philipps University Marburg
  • University Hospital Schleswig-Holstein
  • University of Pennsylvania

Registry information

Official study title

A Randomized Controlled Trial of Bilateral Subthalamic Stimulation in Patients With Parkinson's Disease and Impulse Control Disorders

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Jul 12, 2024
Registry last updated
Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.